免疫|全球排名第六的癌症,中国患者等待的免疫一线治疗终于要来了!( 三 )


参考文献:
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, N Engl J Med 2008;359:1116-27
Burtness B, Harrington KJ, Greil R,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Oct 31: S0140-6736(19)32591-7
Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwise for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018; 0:1-31.
Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115‐132.
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC).ASCO 2019 Oral Abstract 6002
【免疫|全球排名第六的癌症,中国患者等待的免疫一线治疗终于要来了!】http://sq.nmpa.gov.cn/datasearch_nmpa/schedule/search.jsp?tableId=43&tableName=TABLE43&columnName=COLUMN464,COLUMN475&title1=药品注册进度查询

推荐阅读